RemeGen Published P-II Clinical Study Results of Telitacicept for Primary Sjogren's Syndrome in Rheumatology Journal
Shots:
- The P-II study evaluating telitacicept (160 & 240mg, qw for 24wks.) vs PBO. The study was led by Professor Zeng Xiaofeng from the Department of Rheumatology and Immunology in Peking Union Medical College Hospital
- The results showed a significant improvement in EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) scores with mean changes from a baseline of 0.6 ± 4.55, -3.3 ± 2.73, and -1.3 ± 4.14 in the PBO, 160mg, and 240mg groups, respectively
- Change in ESSDAI was slower over PBO for 160mg group at 24wk. using mixed model for repeated measures (MMRM), was well-tolerated with no deaths or SAEs were reported & showed a promising clinical benefit, improving ESSDAI scores, MFI-20, and reducing immunoglobulin levels
Ref: PRNewswire | Image: RemeGen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
